Home › NDC Lookup › RxCUI directory › RxCUI 2711795

Meloxicam 20 MG / rizatriptan 10 MG Oral Tablet [Symbravo] — RxCUI 2711795

Name: Meloxicam 20 MG / rizatriptan 10 MG Oral Tablet [Symbravo] (RxCUI 2711795)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2711795 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2711795

Official nameMeloxicam 20 MG / rizatriptan 10 MG Oral Tablet [Symbravo]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asSYMBRAVO 20 MG / 10 MG Oral Tablet

FDA products mapped1

Package NDCs mapped3

Reported Medicaid activity (SDUD)1,664 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Rizatriptan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Rizatriptan stops a migraine that's already started — it's not a preventive medication. You take it when a migraine hits, and it works by narrowing blood vessels in the brain and q...
What exactly does rizatriptan do — will it prevent my migraines?
Take it as soon as you recognize a migraine coming on — the earlier the better. You don't have to wait until the pain is severe. If the headache goes away and then comes back, you...
When should I take it — right when the headache starts, or should I wait?

📖 Read our full Rizatriptan guide →

🕸️ Concept Web — How Meloxicam 20 MG / rizatriptan 10 MG Oral Tablet... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Meloxicam 20 MG / rizatriptan 10 MG Oral Tablet [Symbravo] RxCUI 2711795 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 3

The active substance itself — no strength, form, or brand attached yet.
- Meloxicam 41493 IN
- Rizatriptan 88014 IN
- Meloxicam / rizatriptan 2710482 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Symbravo 2711790 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Meloxicam / rizatriptan Oral Tablet 2711788 SCDF
- Meloxicam / rizatriptan Oral Product 2711786 SCDG
- Meloxicam / rizatriptan Pill 2711787 SCDG
- Meloxicam / rizatriptan Oral Tablet [Symbravo] 2711794 SBDF
- Symbravo Oral Product 2711792 SBDG
- Symbravo Pill 2711793 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Meloxicam 20 MG / rizatriptan 10 MG Oral Tablet 2711789 SCD
- Meloxicam 20 MG 2711785 SCDC
- Rizatriptan 10 MG 330765 SCDC
- Meloxicam 20 MG / rizatriptan 10 MG [Symbravo] 2711791 SBDC

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Meloxicam 20 MG / rizatriptan 10 MG Oral Tablet SCD · 2711789
Meloxicam 20 MG SCDC · 2711785
Rizatriptan 10 MG SCDC · 330765
Meloxicam / rizatriptan Oral Tablet SCDF · 2711788
Meloxicam / rizatriptan Oral Product SCDG · 2711786
Meloxicam / rizatriptan Pill SCDG · 2711787

Brand-Name Concepts

Meloxicam 20 MG / rizatriptan 10 MG [Symbravo] SBDC · 2711791
Meloxicam / rizatriptan Oral Tablet [Symbravo] SBDF · 2711794
Symbravo Oral Product SBDG · 2711792
Symbravo Pill SBDG · 2711793
Symbravo BN · 2711790

📦 FDA Products & Package NDCs

1 product · 3 package NDCs

3 package NDCs map to RxCUI 2711795 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
81968-0020-02	1 BOTTLE in 1 CARTON (81968-020-02) / 2 TABLET in 1 BOTTLE	SYMBRAVO	Axsome Therapeutics, Inc.	2025-11-21
81968-0020-03	1 BOTTLE in 1 CARTON (81968-020-03) / 3 TABLET in 1 BOTTLE	SYMBRAVO	Axsome Therapeutics, Inc.	2025-05-19
81968-0020-09	9 TABLET in 1 BOTTLE (81968-020-09)	SYMBRAVO	Axsome Therapeutics, Inc.	2025-05-19

Observed labelers: Axsome Therapeutics, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ea · median

$122.6770

Range $122.6770–$122.6770 · middle 50% $122.6770–$122.6770 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.